Please use this identifier to cite or link to this item: https://hdl.handle.net/10356/106322
Title: Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models
Authors: Jain, Mukul R.
Giri, Suresh R.
Bhoi, Bibhuti
Trivedi, Chitrang
Rath, Akshyaya
Rathod, Rohan
Ranvir, Ramchandra
Kadam, Shekhar
Patel, Hiren
Swain, Prabodha
Roy, Sib Sankar
Das, Nabanita
Karmakar, Eshani
Wahli, Walter
Patel, Pankaj R.
Keywords: NAFLD
Science::Medicine
Dual‐PPAR Agonist
Issue Date: 2017
Source: Jain, M. R., Giri, S. R., Bhoi, B., Trivedi, C., Rath, A., Rathod, R., . . . Patel, P. R. (2018). Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models. Liver International, 38(6), 1084-1094. doi:10.1111/liv.13634
Series/Report no.: Liver International
Abstract: Background & Aims: Non‐alcoholic fatty liver disease (NAFLD) and non‐alcoholic steatohepatitis (NASH) are common clinico‐pathological conditions that affect millions of patients worldwide. In this study, the efficacy of saroglitazar, a novel PPARα/γ agonist, was assessed in models of NAFLD/NASH. Methods & Results: HepG2 cells treated with palmitic acid (PA;0.75 mM) showed decreased expression of various antioxidant biomarkers (SOD1, SOD2, glutathione peroxidase and catalase) and increased expression of inflammatory markers (TNFα, IL1β and IL6). These effects were blocked by saroglitazar, pioglitazone and fenofibrate (all tested at 10μM concentration). Furthermore, these agents reversed PA‐mediated changes in mitochondrial dysfunction, ATP production, NFkB phosphorylation and stellate cell activation in HepG2 and HepG2‐LX2 Coculture studies. In mice with choline‐deficient high‐fat diet‐induced NASH, saroglitazar reduced hepatic steatosis, inflammation, ballooning and prevented development of fibrosis. It also reduced serum alanine aminotransferase, aspartate aminotransferase and expression of inflammatory and fibrosis biomarkers. In this model, the reduction in the overall NAFLD activity score by saroglitazar (3 mg/kg) was significantly more prominent than pioglitazone (25 mg/kg) and fenofibrate (100 mg/kg). Pioglitazone and fenofibrate did not show any improvement in steatosis, but partially improved inflammation and liver function. Antifibrotic effect of saroglitazar (4 mg/kg) was also observed in carbon tetrachloride‐induced fibrosis model. Conclusions: Saroglitazar, a dual PPARα/γ agonist with predominant PPARα activity, shows an overall improvement in NASH. The effects of saroglitazar appear better than pure PPARα agonist, fenofibrate and PPARγ agonist pioglitazone.
URI: https://hdl.handle.net/10356/106322
http://hdl.handle.net/10220/49606
ISSN: 1478-3223
DOI: 10.1111/liv.13634
Rights: © 2017 Cadila Healthcare Ltd., Liver International Published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
Fulltext Permission: open
Fulltext Availability: With Fulltext
Appears in Collections:LKCMedicine Journal Articles

Files in This Item:
File Description SizeFormat 
liv.13634.pdf1.66 MBAdobe PDFThumbnail
View/Open

Google ScholarTM

Check

Altmetric


Plumx

Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.